Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03177460
Title Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

prostate adenocarcinoma

Therapies

Daratumumab

Edicotinib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.